Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT001 in Adult Patients With Chronic Spontaneous Urticaria
NCT07717905Phase 2Recruiting
- Sponsor
- Bambusa Therapeutics
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BBT001 in chronic spontaneous urticaria (CSU) (8 cohorts), sponsored by Bambusa Therapeutics. Primary endpoints: Adverse Events at Day 183, Change in vital sign measurements at Day 183 and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
BBT001
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07717905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717905.